Compares docetaxel with newer hormone drugs in advanced prostate cancer
Tests docetaxel against abiraterone or enzalutamide in men with advanced, treatment-resistant prostate cancer.
Key facts
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Where
- Alba, Ancona, Bologna, Carpi, Genoa, L'aquila, Macerata, Milan, Modena, Naples, Parma, Reggio Emilia, Rimini, Rome, San Giovanni Rotondo, Terni, Trento, Udine, Varese, and Viterbo, ItalySee the 21 sites
- Registry title
- RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic factors (RADAR-1 CRPC)
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 68 people, planned
- Started
- 1 Oct 2020
- Expected to end
- 19 Apr 2027
- Type of study
- Interventional
- Record updated
- 26 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and no longer responds to hormone-lowering treatment. They must have no known BRCA1/2 gene change, or an unknown BRCA status, and at least one sign of a harder course.
- Age
- 18 years and above
- Sex
- Men only
- Disease stage
- Prostate cancer (adenocarcinoma) that has spread to other parts of the body and has grown despite castration (mCRPC). At least one negative prognostic feature is needed: mild pain, or no pain with PSA ≥80 ng/dl, Gleason Score ≥ 8, PSA doubling time ≤ 3 months, or under 1 year from start of ADT to CRPC. ECOG performance status 0 or 2.
- Earlier treatment
- Must be surgically or medically castrated, with testosterone below 50 ng/dL. No earlier chemotherapy or biologic therapy for prostate cancer. Earlier bicalutamide is allowed. Earlier new-generation androgen receptor inhibitors are allowed only if stopped at least 1 year ago, or if used for more than 36 months without progression.
- Biomarker or test result
- No mutation in the BRCA1 or BRCA2 genes, or BRCA status unknown because the tumour tissue could not be tested. Testosterone below 50 ng/dL (below 2.0 nM).
Main reasons for not taking part
- Known brain metastasis
- Serious heart disease, or uncontrolled heart rhythm problems
- Another cancer diagnosed within the last 5 years (except non-muscle-invasive bladder cancer)
- More than 10% small cell carcinoma of the prostate
- Use of strong opiate painkillers for cancer pain (codeine and tramadol are allowed)
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Willing and able to provide written informed consent
- Adequate bone marrow and chemistry values defined as: a. Hemoglobin ≥ 10.0 g/dL independent of transfusion b. Neutrophil count ≥1500 x 109/L c. Platelet count ≥100,000/μL d. Serum albumin ≥ 3.5 g/dL e. Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min f. Serum potassium ≥ 3.5 mmol/L g. Liver function: - Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert’s disease); - AST or ALT < 2.5 x ULN
- Able to swallow the study drug whole as a tablet
- Life expectancy of at least 6 months
- Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration
- Male aged 18 years and above
- Histologically or cytological confirmed adenocarcinoma of the prostate
- Metastatic disease documented by positive bone scan or metastatic lesions other than liver or visceral metastasis on CT, MRI. If lymph node metastasis is the only evidence of metastasis, it must be ≥ 2 cm in diameter. Alternatively, metastatic disease can be diagnosed by PET-Choline or PSMA
- Prostate cancer progression documented by PSA according to PCWG2 or radiographic progression according to modified RECIST criteria
- At least one negative prognostic features between: I. Mildly symptomatic prostate cancer defined as per BPI Question #3 (worst pain in last 24 hours) value 2 or 3 or II. Asymptomatic prostate cancer defined as per BPI Question #3 (worst pain in last 24 hours) value 0 or 1 and at least one between - PSA≥80 ng/dl ; - Gleason Score ≥ 8; - PSA doubling time ≤ 3 months; - Time from start ADT to CRPC less < 1 year
- No evidence of mutation in BRCA1 or genes or tumor tissue not evaluated for quality reasons (status unknown)
- Surgically or medically castrated, with testosterone levels of < 50 ng/dL (< 2.0 nM)
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 2
Who cannot take part
- Other malignancy with a previous diagnosis within 5 years (with the exclusions of NMIBC)
- Concomitant medications as reported in section 7
- Previous cytotoxic chemotherapy, or biologic therapies for the treatment of castrationsensitive or castration-resistant prostate cancer (prior use of bicalutamide is permitted). Previous use of new generation androgen receptor inhibitors for castration-sensitive disease is permitted if at least one year has passed since their discontinuation or if treatment has lasted longer than 36 months without evidence of biochemical and radiological progression
- Radiation therapy for treatment of the primary tumour within 6 weeks of Cycle 1, Day 1
- Radiation or radionuclide therapy for treatment of metastatic CRPC and CSPC
- Active infection or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated
- Active or symptomatic viral hepatitis or chronic liver disease
- Uncontrolled Atrial Fibrillation, or other uncontrolled cardiac arrhythmia requiring therapy
- Known hypersensitivity to docetaxel, abiraterone or enzalutamide active principles and any excipients
- Use of major opiate analgesics for cancer-related pain (codeine and tramadol are allowed)
- Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg). Patients with a history of hypertension are allowed provided blood pressure is controlled by antihypertensive treatment
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms) or history of additional risk factors for “torsaides de pointes” (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) or the use of concomitant medications that prolong the QT/QTc interval (at least those of class IA and III)
- Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 50% at baseline
- Pathological finding consistent with small cell carcinoma of the prostate greater than 10%
- Known brain metastasis
- Bicalutamide, nilutamide within 6 weeks of Cycle 1 Day 1
This trial is currently available in Italy.
- Azienda Sanitaria Locale Cn2 Alba-BraAlba, ItalyTaking people
- Azienda Ospedaliero-Universitaria delle MarcheAncona, ItalyTaking people
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyTaking people
- Azienda Unita Sanitaria Locale Di ModenaCarpi, ItalyTaking people
- IRCCS Ospedale Policlinico San MartinoGenoa, ItalyTaking people
- Azienda Sanitaria Locale Avezzano Sulmona L'AquilaL'aquila, ItalyTaking people
- Ospedale Generale Provinciale Di MacerataMacerata, ItalyTaking people
- Istituto Europeo di Oncologia s.r.lMilan, ItalyTaking people
- Azienda Ospedaliero - Universitaria di ModenaModena, ItalyTaking people
- Azienda Ospedaliera Universitaria Federico II Di NapoliNaples, ItalyTaking people
- Azienda Ospedaliero Universitaria ParmaParma, ItalyTaking people
- Azienda USL IRCCS di Reggio EmiliaReggio Emilia, ItalyTaking people
- Azienda Unita Sanitaria Locale Della RomagnaRimini, ItalyTaking people
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
- Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata FonRome, ItalyTaking people
- Casa Sollievo della SofferenzaSan Giovanni Rotondo, ItalyTaking people
- Azienda Ospedaliera S Maria Di TerniTerni, ItalyTaking people
- Azienda Provinciale Per I Servizi SanitariTrento, ItalyTaking people
- Azienda Sanitaria Universitaria Friuli CentraleUdine, ItalyTaking people
- Azienda Ospedaliera Ospedale Di Circolo E Fondazione MacchiVarese, ItalyTaking people
- Azienda Sanitaria Locale ViterboViterbo, ItalyTaking people
About the trial
What the trial wants to find out
To investigate if docetaxel is superior to Androgen Receptor-targeted agent (abiraterone+prednisone or enzalutamide) for treatment of patients with mCRPC BRCA negative or unknown and negative prognostic factors in terms of PFS.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic factors (RADAR-1 CRPC)
- Plain-language title
- Compares docetaxel with newer hormone drugs in advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 26 November 2024